OUD Care Service Improvement with Prolonged-release Buprenorphine in Prisons: Cost Estimation Analysis

References

• Dematteis M, Auriacombe M, D’Agnone O, et al. Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. Expert Opin Pharmacother. 2017;00(00):14656566.2017.1409722. doi:10.1080/14656566.2017.1409722
   Web of Science ®Google Scholar
• Lang K, Neil J, Wright J, Dell CA, Berenbaum S, El-Aneed A. Qualitative investigation of barriers to accessing care by people who inject drugs in Saskatoon, Canada: perspectives of service providers. Subst Abuse Treat Prev Policy. 2013;8:35. doi:10.1186/1747-597X-8-35
   PubMed Web of Science ®Google Scholar
• HM Inspectorate of Prisons. Changing patterns of substance misuse in adult prisons and service responses. 2015.
   Google Scholar
• World Health Organization. Regional Office for Europe. Preventing overdose deaths in the criminal-justice system. 2014.
   Google Scholar
• Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group. Drug Misuse and Dependence: UK Guidelines on Clinical Management. London: Global and Public Health/Population Health/Healthy Behaviours/25460; 2017.
   Google Scholar
• Coid J, Carvell A, Kittler Z, Healey A, Henderson J Opiates, criminal behaviour, and methadone treatment. 2000.
   Google Scholar
• Jewkes Y, Crewe B, Bennett J. Handbook on Prisons. 2nd ed. Oxford: Taylor & Francis; 2016.
   Google Scholar
• Cooper R, Labour MP, Lancashire W House of commons health and social care committee. Prison health. Twelfth Report of Session 2017–19. 2018;November.
   Google Scholar
• Northamptonshire Healthcare NHS Foundation Trust. MMPr027/HMP controlled drug procedure for HMP bedford.; 2018.
   Google Scholar
• RCGP Secure Environments Group. Safer prescribing in prisons. Guidance for clinicians. 2011.
   Google Scholar
• Nielsen S, Degenhardt L, Larance B, Gowing L, Kehler C, Lintzeris N Opioid agonist treatment for pharmaceutical opioid dependent people (protocol). 2016. doi:10.1002/14651858.CD011117
   Google Scholar
• Mattick R, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence (Review). Cochrane Database Syst Rev. 2009;(3). doi:10.1002/14651858.CD002209.pub2.www.cochranelibrary.com
   Web of Science ®Google Scholar
• Stöver H, Michels II. Drug use and opioid substitution treatment for prisoners. Harm Reduct J. 2010;7:17. doi:10.1186/1477-7517-7-17
   Web of Science ®Google Scholar
• Bi-Mohammed Z, Wright N, Hearty P, King N, Gavin H. Prescription opioid abuse in prison settings: a systematic review of prevalence, practice and treatment responses. Drug Alcohol Depend. 2017;171:122–131. doi:10.1016/j.drugalcdep.2016.11.032
   PubMed Web of Science ®Google Scholar
• Webster R Service user views on Opioid Substitute Treatment in Prison and on Release.
   Google Scholar
• Public Health England. Secure setting statistics from the National Drug Treatment Monitoring System (NDTMS). 2017.
   Google Scholar
• Bukten A, Skurtveit S, Tverdal A, Strang J, Clausen T. High risk of overdose death following release from prison: variations in mortality during a 15-year observation period. Addiction. 2017;112(8):1432–1439. doi:10.1111/add.13803
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Buvidal Buprenorphine, Summary of Opinion (Initial Authorisation). 2018.
   Google Scholar
• National Institute for Health and Care Excellence. Evidence review. Opioid dependence: buprenorphine prolonged-release injection (Buvidal). 2019.
   Google Scholar
• Lofwall MR, Walsh SL, Nunes EV, et al. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder a randomized clinical trial. JAMA Intern Med. 2018;178(6):764–773. doi:10.1001/jamainternmed.2018.1052
   PubMed Web of Science ®Google Scholar
• Frost M, Bailey GL, Lintzeris N, et al. Long‐term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult outpatients with opioid use disorder. Addiction. 2019:add.14636. doi:10.1111/add.14636.
   Web of Science ®Google Scholar
• University of Vermont. Opioid epidemic linked to childhood emotional abuse, study shows Findings suggests new treatment approaches for opioid abusers. ScienceDaily. 2017. doi:10.1016/j.ad
   Google Scholar
• Healthcare Improvement Scotland. SMC 2169 buprenorphine 8/16/24/32/64/96/128mg prolonged-release solution for injection (Buvidal ^®). 2019;(August):1–13.
   Google Scholar
• Vorspan F, Hjelmström P, Simon N, et al. What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine. Expert Opin Drug Deliv. 2019;16(9):907–914. doi:10.1080/17425247.2019.1649252
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Evidence review opioid dependence: buprenorphine prolonged- release injection (Buvidal); 2019. https://www.nice.org.uk/advice/es19/evidence/evidence-review-pdf-6666819661. Accessed August 5, 2020.
   Google Scholar
• Dunlop A Depot buprenorphine for opioid dependence in prisons in NSW, Australia. Lisbon Addiction.
   Google Scholar
• Prison Health Services Methadone at HMP The Mount. Available from: https://bulger.co.uk/prison/methadoneblog.htm. Accessed August 10, 2020.
   Google Scholar
• Ministry of Justice. Population Bulletin: Monthly April 2019. 2019.
   Google Scholar
• NICE. TA 114 Methadone and buprenorphine for the management of opioid dependence. 2007. doi:10.2165/11632820-000000000-00000
   Google Scholar
• Expert communication. 2019.
   Google Scholar
• Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;j1550. Doi:10.1136/bmj.j1550.
   Web of Science ®Google Scholar
• North East Ambulance Service NHS Foundation Trust. Freedom of Information Act 2000 – Information Request FOI.18.074. 2018.
   Google Scholar
• Prisons & Probation Ombudsman. Annual Report 2017 – 18. 2018.
   Google Scholar
• Marsden J, Stillwell G, Jones H, et al. Does exposure to opioid substitution treatment in prison reduce the risk of death after release? Natl Prospect Obs Study Engl. 2017;112:1408–1418. doi:10.1111/add.13779
   Web of Science ®Google Scholar
• Ministry of Justice. Offender management statistics quarterly: adjudications. 2017.
   Google Scholar
• O’Hagan A, Hardwick R. Behind bars: the truth about drugs in prisons. Forensic Res Criminol Int J. 2017;5(3):00158. doi:10.15406/frcij.2017.05.00158
   Google Scholar
• Kopak AM, Dean LV, Proctor SL, Miller L, Ho NG. Effectiveness of the rehabilitation for addicted prisoners trust (RAPt) programme. J Subst Use. 2015;20(4):254–261. doi:10.3109/14659891.2014.904938
   Web of Science ®Google Scholar
• NHS. NHS Electronic Drug Tariff. 2019.
   Google Scholar
• Medilogic UK. Personal communication. 2018.
   Google Scholar
• HM Prison & Probation Service. 10336 - Band 4 - Supervising Officer.
   Google Scholar
• Care UK. Staff Nurse vacancy.
   Google Scholar
• Care UK. Pharmacy Technician vacancy.
   Google Scholar
• Care UK. Pharmacist vacancy.
   Google Scholar
• NHS. Consultant Psychiatrist (Prison Service).
   Google Scholar
• Scott D. Saying NO to the mega prison. Justics Power Res. 2018;2(1):204–221.
   Google Scholar
• Ministry of Justice. Costs per Place and Costs per Prisoner by Individual Prison. 2018.
   Google Scholar
• Kenworthy J, Yi Y, Wright A, Brown J, Maria Madrigal A, Dunlop WCN. Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost effectiveness modelling study. J Med Econ. 2017;20(7):740–748. doi:10.1080/13696998.2017.1325744
   PubMed Web of Science ®Google Scholar